The period saw a shift toward pharmacologic immunosuppression as the primary means to sustain graft function, complemented by investigations into whether rejection could be reversed to yield longer-term tolerance. Crossmatching and serologic assessment began shaping donor selection and pretransplant risk, with early demonstrations that preformed antibodies could predict rapid graft loss. Methodologically, reports combined clinical observation with therapeutic trials to establish how pharmacologic strategies could extend kidney survival and inform subsequent regimens. Historical Significance: These findings established immunosuppression as the cornerstone of kidney transplantation and introduced the concept that rejection could be managed toward tolerance, reshaping long-term outcomes. The critical recognition of hyperacute rejection and the development of crossmatch testing transformed pretransplant evaluation and risk stratification, laying the groundwork for modern compatibility testing and personalized transplant planning.